Showing results (61-70 of 95) with videos related to

Sort By:
Pageof 10
Thrombosis and Haemostasis|March 20, 2015
A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatranStephan Glund, Viktoria Moschetti, Stephen Norris, et al.
Expert Opinion on Investigational Drugs|November 5, 2016
Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjectsChristopher Wynne, Mario Altendorfer, Ivo Sonderegger, et al.
Frontiers in Behavioral Neuroscience|October 9, 2023
Challenges and advanced concepts for the assessment of learning and memory function in miceBenjamin Lang, Pia Kahnau, Katharina Hohlbaum, et al.
Nucleic Acids Research|June 16, 2021
Matrix-screening reveals a vast potential for direct protein-protein interactions among RNA binding proteinsBenjamin Lang, Jae-Seong Yang, Mireia Garriga-Canut, et al.
Rheumatology and Therapy|July 1, 2018
Similar Pharmacokinetics of the Adalimumab (Humira®) Biosimilar BI 695501 Whether Administered via Subcutaneous Autoinjector or Prefilled Syringe (VOLTAIRE®-AI and VOLTAIRE®-TAI): Phase 1, Randomized, Open-Label, Parallel-Group TrialsSteven Ramael, Benjamin Van Hoorick, Renger Tiessen, et al.
Frontiers in Immunology|December 6, 2021
Conserved Induction of Distinct Antiviral Signalling Kinetics by Primate Interferon Lambda 4 ProteinsCuncai Guo, Dorothee Reuss, Jonathon D Coey, et al.
RNA (New York, N.Y.)|July 17, 2020
Determination of primary microRNA processing in clinical samples by targeted pri-miR-sequencingThomas Conrad, Evgenia Ntini, Benjamin Lang, et al.
Pharmaceutical Statistics|October 16, 2020
Assessing goodness-of-fit for evaluation of dose-proportionalityMartin J Wolfsegger, Alexander Bauer, Detlew Labes, et al.
British Journal of Clinical Pharmacology|February 24, 2017
Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studiesStephen Norris, Steven Ramael, Ippei Ikushima, et al.
The Journal of Allergy and Clinical Immunology|October 22, 2021
Pustular psoriasis: Molecular pathways and effects of spesolimab in generalized pustular psoriasisPatrick Baum, Sudha Visvanathan, Sandra Garcet, et al.
Pageof 10